Logo image of ELUT

ELUTIA INC (ELUT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELUT - US05479K1060 - Common Stock

0.9204 USD
+0.08 (+9.27%)
Last: 1/21/2026, 8:13:06 PM
0.9199 USD
0 (-0.05%)
Pre-Market: 1/22/2026, 7:34:12 AM
Fundamental Rating

1

Taking everything into account, ELUT scores 1 out of 10 in our fundamental rating. ELUT was compared to 525 industry peers in the Biotechnology industry. ELUT has a bad profitability rating. Also its financial health evaluation is rather negative. ELUT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ELUT has reported negative net income.
  • In the past year ELUT has reported a negative cash flow from operations.
  • ELUT had negative earnings in each of the past 5 years.
  • ELUT had a negative operating cash flow in each of the past 5 years.
ELUT Yearly Net Income VS EBIT VS OCF VS FCFELUT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • ELUT has a Return On Assets of -90.02%. This is in the lower half of the industry: ELUT underperforms 72.57% of its industry peers.
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROIC N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ELUT Yearly ROA, ROE, ROICELUT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K -3K -4K

1.3 Margins

  • With a decent Gross Margin value of 45.97%, ELUT is doing good in the industry, outperforming 74.67% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ELUT has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for ELUT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
ELUT Yearly Profit, Operating, Gross MarginsELUT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

More info and screens

0

2. Health

2.1 Basic Checks

  • ELUT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ELUT has been increased compared to 1 year ago.
  • The number of shares outstanding for ELUT has been increased compared to 5 years ago.
  • Compared to 1 year ago, ELUT has a worse debt to assets ratio.
ELUT Yearly Shares OutstandingELUT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ELUT Yearly Total Debt VS Total AssetsELUT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -14.06, we must say that ELUT is in the distress zone and has some risk of bankruptcy.
  • ELUT has a Altman-Z score of -14.06. This is in the lower half of the industry: ELUT underperforms 77.90% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -14.06
ROIC/WACCN/A
WACC13.42%
ELUT Yearly LT Debt VS Equity VS FCFELUT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

  • A Current Ratio of 0.44 indicates that ELUT may have some problems paying its short term obligations.
  • ELUT has a worse Current ratio (0.44) than 90.67% of its industry peers.
  • A Quick Ratio of 0.40 indicates that ELUT may have some problems paying its short term obligations.
  • The Quick ratio of ELUT (0.40) is worse than 90.86% of its industry peers.
Industry RankSector Rank
Current Ratio 0.44
Quick Ratio 0.4
ELUT Yearly Current Assets VS Current LiabilitesELUT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

  • ELUT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.95%, which is quite impressive.
  • Looking at the last year, ELUT shows a very negative growth in Revenue. The Revenue has decreased by -33.02% in the last year.
  • Measured over the past years, ELUT shows a very negative growth in Revenue. The Revenue has been decreasing by -10.69% on average per year.
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%

3.2 Future

  • The Earnings Per Share is expected to grow by 22.61% on average over the next years. This is a very strong growth
  • The Revenue is expected to decrease by -8.34% on average over the next years.
EPS Next Y81.83%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ELUT Yearly Revenue VS EstimatesELUT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
ELUT Yearly EPS VS EstimatesELUT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • ELUT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ELUT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELUT Price Earnings VS Forward Price EarningsELUT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELUT Per share dataELUT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • ELUT's earnings are expected to grow with 22.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.85%
EPS Next 3Y22.61%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ELUT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ELUTIA INC

NASDAQ:ELUT (1/21/2026, 8:13:06 PM)

Premarket: 0.9199 0 (-0.05%)

0.9204

+0.08 (+9.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-12
Earnings (Next)05-06
Inst Owners39.76%
Inst Owner ChangeN/A
Ins Owners2.92%
Ins Owner Change8.36%
Market Cap39.30M
Revenue(TTM)21.08M
Net Income(TTM)-26.47M
Analysts82.5
Price Target3.57 (287.87%)
Short Float %0.66%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.22%
Min EPS beat(2)-32.64%
Max EPS beat(2)43.07%
EPS beat(4)2
Avg EPS beat(4)15.16%
Min EPS beat(4)-32.64%
Max EPS beat(4)52.18%
EPS beat(8)3
Avg EPS beat(8)-32.92%
EPS beat(12)5
Avg EPS beat(12)-27.63%
EPS beat(16)6
Avg EPS beat(16)-23.29%
Revenue beat(2)0
Avg Revenue beat(2)-28.63%
Min Revenue beat(2)-51.01%
Max Revenue beat(2)-6.26%
Revenue beat(4)0
Avg Revenue beat(4)-19.38%
Min Revenue beat(4)-51.01%
Max Revenue beat(4)-6.26%
Revenue beat(8)1
Avg Revenue beat(8)-12.66%
Revenue beat(12)2
Avg Revenue beat(12)-9.2%
Revenue beat(16)4
Avg Revenue beat(16)-6.52%
PT rev (1m)0%
PT rev (3m)-36.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.24%
EPS NY rev (1m)16.04%
EPS NY rev (3m)25.83%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-42.59%
Revenue NY rev (1m)-6.27%
Revenue NY rev (3m)-23.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.68
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0.49
BVpS-1.03
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.97%
FCFM N/A
ROA(3y)-94.61%
ROA(5y)-70.28%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.05%
GM growth 5Y-0.95%
F-Score3
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.32%
Cap/Sales 5.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.44
Quick Ratio 0.4
Altman-Z -14.06
F-Score3
WACC13.42%
ROIC/WACCN/A
Cap/Depr(3y)14.22%
Cap/Depr(5y)13.83%
Cap/Sales(3y)1.73%
Cap/Sales(5y)1.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.73%
EPS Next Y81.83%
EPS Next 2Y33.85%
EPS Next 3Y22.61%
EPS Next 5YN/A
Revenue 1Y (TTM)-33.02%
Revenue growth 3Y-19.88%
Revenue growth 5Y-10.69%
Sales Q2Q%-43.89%
Revenue Next Year-24.6%
Revenue Next 2Y-21.45%
Revenue Next 3Y-8.34%
Revenue Next 5YN/A
EBIT growth 1Y10.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.81%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-83.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.24%
OCF growth 3YN/A
OCF growth 5YN/A

ELUTIA INC / ELUT FAQ

Can you provide the ChartMill fundamental rating for ELUTIA INC?

ChartMill assigns a fundamental rating of 1 / 10 to ELUT.


Can you provide the valuation status for ELUTIA INC?

ChartMill assigns a valuation rating of 1 / 10 to ELUTIA INC (ELUT). This can be considered as Overvalued.


Can you provide the profitability details for ELUTIA INC?

ELUTIA INC (ELUT) has a profitability rating of 1 / 10.


How financially healthy is ELUTIA INC?

The financial health rating of ELUTIA INC (ELUT) is 0 / 10.